AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27709460 — intervention group
Group type: COMPARATOR
Intervention: Ingestion of dabigatran after a meal (DE-M)
Number of subjects: 117
Study 27709460 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effectiveness using either strategy or a combination
Number of subjects: 117
Study 27709460 — intervention group
Group type: EXPERIMENTAL
Intervention: DE-P (initial strategy)
Number of subjects: 117
Study 27709460 — intervention group
Group type: COMPARATOR
Intervention: DE-M (initial strategy)
Number of subjects: 117
Study 27710003 — intervention group
Group type: EXPERIMENTAL
Intervention: FORNET (forensic offender rehabilitation narrative exposure therapy)
Number of subjects: 39
Study 27710003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 39
Study 27710003 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 39
Study 27710087 — intervention group
Group type: EXPERIMENTAL
Intervention: ProjectHeartforGirls.com web-based program
Number of subjects: 36
Study 27711228 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/MVA Vaccination (GOVX-B11)
Number of subjects: 9
Study 27712711 — intervention group
Group type: EXPERIMENTAL
Intervention: RESQ-7 (7-day recall)
Number of subjects: 446
Study 27712711 — intervention group
Group type: COMPARATOR
Intervention: RESQ-eD (twice daily for 7 days)
Number of subjects: 446
Study 27712711 — intervention group
Group type: EXPERIMENTAL
Intervention: RESQ-7
Number of subjects: 446
Study 27712711 — intervention group
Group type: COMPARATOR
Intervention: RESQ-eD
Number of subjects: 446
Study 27712741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioband system
Number of subjects: 31
Study 27712877 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy with controlled hypovolemia
Number of subjects: 138
Study 27712877 — intervention group
Group type: COMPARATOR
Intervention: No phlebotomy (control group)
Number of subjects: 138
Study 27713075 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual wheelchairs
Number of subjects: 421
Study 27713075 — intervention group
Group type: EXPERIMENTAL
Intervention: Power wheelchairs
Number of subjects: 421
Study 27713075 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 421
Study 27713075 — intervention group
Group type: EXPERIMENTAL
Intervention: Income
Number of subjects: 421
Study 27713637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib at a starting dose of 50 mg/day on a 4-weeks-on/2-weeks-off schedule
Number of subjects: 348
Study 27713637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 348
Study 27714595 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 µg/g and Betamethasone 0.5 mg/g aerosol foam
Number of subjects: 426
Study 27714595 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 426
Study 27714677 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination
Number of subjects: 0
Study 27716119 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular prognostic test (GUCY2C)
Number of subjects: 41
Study 27716131 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 0
Study 27716131 — intervention group
Group type: COMPARATOR
Intervention: Myocardial perfusion scintigraphy (MPS)
Number of subjects: 0
Study 27716131 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated CCTA metric
Number of subjects: 0
Study 27716131 — intervention group
Group type: COMPARATOR
Intervention: Integrated MPS measure
Number of subjects: 0
Study 27716162 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavioral therapy (CBT-E)
Number of subjects: 0
Study 27716162 — intervention group
Group type: COMPARATOR
Intervention: Control group without an eating disorder
Number of subjects: 0
Study 27716218 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based football (one hour twice weekly for six months)
Number of subjects: 200
Study 27716218 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 27716244 — intervention group
Group type: EXPERIMENTAL
Intervention: HRP2 tests
Number of subjects: 424
Study 27716244 — intervention group
Group type: EXPERIMENTAL
Intervention: pLDH test
Number of subjects: 424
Study 27716244 — intervention group
Group type: COMPARATOR
Intervention: Blood smear microscopy (gold standard)
Number of subjects: 424
Study 27716304 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU vitamin D daily for 14 days followed by 10,000 IU per day for 7 days
Number of subjects: 91
Study 27716344 — intervention group
Group type: EXPERIMENTAL
Intervention: SASHA
Number of subjects: 40
Study 27716344 — intervention group
Group type: EXPERIMENTAL
Intervention: ShMOLLI
Number of subjects: 40
Study 27716344 — intervention group
Group type: EXPERIMENTAL
Intervention: MOLLI
Number of subjects: 40
Study 27716343 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of collagen remodeling (including degradation fragments of collagen type IV C6M)
Number of subjects: 1000
Study 27716370 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS with a VOT (vascular occlusion test)
Number of subjects: 89
Study 27716377 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine biomarkers (cystatin C, NGAL, TIMP-2×IGFBP7) measured at admission and day 3
Number of subjects: 195
Study 27716377 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine TIMP-2×IGFBP7 levels at admission
Number of subjects: 195
Study 27716377 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical parameters and biomarker concentrations
Number of subjects: 195
Study 27716402 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27716819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (100, 150, and 200 mg orally twice daily) combined with low-dose cytarabine (20 mg subcutaneous injection twice daily for 10 days)
Number of subjects: 13
Study 27716819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib combined with low-dose cytarabine (LDAC)
Number of subjects: 13
Study 27717372 — intervention group
Group type: EXPERIMENTAL
Intervention: VENTANA PD-L1 (SP263) Assay
Number of subjects: 181
Study 27717384 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative plasma GDF-15
Number of subjects: 1176
Study 27717384 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model including GDF-15
Number of subjects: 1176
Study 27717384 — intervention group
Group type: COMPARATOR
Intervention: Cleveland-Clinic Acute Renal Failure (CC-ARF) score
Number of subjects: 1176
Study 27717842 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with IBD
Number of subjects: 112
Study 27717842 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (controls)
Number of subjects: 112
Study 27717861 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients at risk of ARDS (Lung Injury Prediction Score of 4 or higher)
Number of subjects: 935
Study 27717861 — intervention group
Group type: COMPARATOR
Intervention: Patients not at risk of ARDS
Number of subjects: 935
Study 27718118 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin (tested using revised broth microdilution method)
Number of subjects: 647
Study 27719673 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of aetiology, diagnosis, and treatment of pre-eclampsia and eclampsia among health care providers.
Number of subjects: 33
Study 27719673 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of magnesium sulphate for eclampsia management.
Number of subjects: 33
Study 27719673 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and guidelines for management of pre-eclampsia.
Number of subjects: 33
Study 27719673 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral practices for pre-eclampsia cases.
Number of subjects: 33
Study 27719678 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers' understanding of hypertension and seizures in pregnancy, including psychological explanations such as stress, tension, and fear.
Number of subjects: 12
Study 27719678 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement of rest, decreased salt intake, iron supplementation, and tetanus vaccination for hypertension management.
Number of subjects: 12
Study 27719678 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of antihypertensives and MgSO by some staff nurses.
Number of subjects: 12
Study 27719680 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-sharing to Lady Health Workers (LHWs) for identification and management of pre-eclampsia
Number of subjects: 33
Study 27719680 — intervention group
Group type: COMPARATOR
Intervention: Current LHW practices
Number of subjects: 33
Study 27719681 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-sharing among CHEWs for detection of early signs of pre-eclampsia
Number of subjects: 71
Study 27720178 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma therapy
Number of subjects: 45
Study 27720178 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 45
Study 27720178 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 45
Study 27720178 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 45
Study 27720178 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive rituximab
Number of subjects: 45
Study 27720278 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray-scale analysis of carotid plaques (GSM, DWAs, black areas)
Number of subjects: 38
Study 27720278 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of discrete white areas (DWAs) in ultrasound analysis
Number of subjects: 38
Study 27720278 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent of plaque black area in any one component
Number of subjects: 38
Study 27720417 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical weight loss maintenance (>10% weight loss)
Number of subjects: 80
Study 27720417 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate maintenance (1-10% weight loss)
Number of subjects: 80
Study 27720417 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain
Number of subjects: 80
Study 27720582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 plus vitamin D
Number of subjects: 0
Study 27722750 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 370
Study 27722750 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 370
Study 27722750 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 370
Study 27722854 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 19
Study 27722854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 19
Study 27722854 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 19
Study 27723665 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-VKA oral anticoagulants (NOACs)
Number of subjects: 6273
Study 27723665 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 6273
Study 27723665 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) therapy
Number of subjects: 6273
Study 27723665 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score
Number of subjects: 6273
Study 27723665 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 6273
Study 27724844 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint surgery
Number of subjects: 644
Study 27724844 — intervention group
Group type: EXPERIMENTAL
Intervention: Back surgery
Number of subjects: 644
Study 27724844 — intervention group
Group type: COMPARATOR
Intervention: Urological surgery
Number of subjects: 644
Study 27724869 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT plaque morphological assessment combined with FFR in group B (patients with TCFA)
Number of subjects: 3
Study 27724869 — intervention group
Group type: COMPARATOR
Intervention: FFR negative lesions without TCFA in group A
Number of subjects: 3
Study 27724869 — intervention group
Group type: COMPARATOR
Intervention: FFR-positive, PCI-treated intermediate lesions in group C
Number of subjects: 3
Study 27724916 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy
Number of subjects: 77
Study 27724916 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 77
Study 27724918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fistula repair surgery
Number of subjects: 364
Study 27724970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of tranexamic acid (TxA) administered after the first blood sample was taken.
Number of subjects: 27
Study 27725146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal microbiota signature for severe IBS
Number of subjects: 149
Study 27725146 — intervention group
Group type: COMPARATOR
Intervention: Fecal and mucosal microbiota analysis
Number of subjects: 149
Study 27725657 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) treatment
Number of subjects: 0
Study 27725657 — intervention group
Group type: COMPARATOR
Intervention: No treatment (unmedicated)
Number of subjects: 0
Study 27726853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification of medical therapy (initiation of aspirin or initiation/increases in dose of ACE inhibitors, ARBs, statins, or β blockers)
Number of subjects: 185
Study 27726853 — intervention group
Group type: COMPARATOR
Intervention: No intensification of medical therapy
Number of subjects: 185
Study 27726853 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 185
Study 27729265 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted retrieval using excimer laser sheath technique
Number of subjects: 251
Study 27729265 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted retrieval
Number of subjects: 251
Study 27729313 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib in combination with irinotecan and cetuximab
Number of subjects: 0
Study 27729332 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI with scoring system for predicting complications
Number of subjects: 1569
Study 27729332 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI with scoring system
Number of subjects: 1569
Study 27729462 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 419
Study 27729462 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-DM)
Number of subjects: 419
Study 27729766 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ALA
Number of subjects: 15
Study 27729766 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ALA
Number of subjects: 15
Study 27729766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg ALA
Number of subjects: 15
Study 27729766 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal prophylaxis medications
Number of subjects: 15
Study 27729854 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Intermittent Theta Burst Stimulation
Number of subjects: 0
Study 27729854 — intervention group
Group type: COMPARATOR
Intervention: Sham-Controlled
Number of subjects: 0
Study 27730010 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR422459 gene therapy
Number of subjects: 22
Study 27730116 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping with pharmacogenetic reports linked to decision support program
Number of subjects: 191
Study 27730116 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva sample collection and genotyping
Number of subjects: 191
Study 27730116 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of decision support software
Number of subjects: 191
Study 27730492 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision rule to assess severity in acute heart failure
Number of subjects: 0
Study 27730492 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical predictors available in the ED
Number of subjects: 0
Study 27732627 — intervention group
Group type: EXPERIMENTAL
Intervention: High educational level (EL)
Number of subjects: 185
Study 27732627 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle educational level (EL)
Number of subjects: 185
Study 27732627 — intervention group
Group type: COMPARATOR
Intervention: Low educational level (EL)
Number of subjects: 185
Study 27733070 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF; 240 mg twice daily)
Number of subjects: 0
Study 27733082 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 week recall version of the UFS-QoL Questionnaire
Number of subjects: 271
Study 27733159 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (moderate-intensity)
Number of subjects: 564
Study 27733159 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy
Number of subjects: 564
Study 27733159 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 564
Study 27733243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously every 2 weeks until disease progression or treatment discontinuation
Number of subjects: 86
Study 27733243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 86
Study 27733347 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomographic angiography
Number of subjects: 10003
Study 27733347 — intervention group
Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 10003
Study 27733374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m² weekly with concurrent standard radiotherapy (60-66 Gy over 6-7 weeks) and panitumumab.
Number of subjects: 44
Study 27733394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D inadequacy (<50 nmol/L)
Number of subjects: 5664
Study 27733394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D concentration
Number of subjects: 5664
Study 27733401 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced intake during the previous week
Number of subjects: 91245
Study 27733401 — intervention group
Group type: EXPERIMENTAL
Intervention: Confinement to bed
Number of subjects: 91245
Study 27733401 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 91245
Study 27733401 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 91245
Study 27733401 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 91245
Study 27733401 — intervention group
Group type: EXPERIMENTAL
Intervention: Low body mass index
Number of subjects: 91245
Study 27733404 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of ultraprocessed food consumption
Number of subjects: 8451
Study 27733404 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of ultraprocessed food consumption
Number of subjects: 8451
Study 27733407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable, fruit, and white rice dietary pattern (VFR)
Number of subjects: 923
Study 27733412 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV/HCV dual infection
Number of subjects: 997
Study 27733412 — intervention group
Group type: COMPARATOR
Intervention: HCV monoinfection
Number of subjects: 997
Study 27733413 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral glucose tolerance test (OGTT) 75 g
Number of subjects: 748
Study 27733413 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated fibronectin (glyFn)
Number of subjects: 748
Study 27733413 — intervention group
Group type: EXPERIMENTAL
Intervention: New screening algorithm based on multivariable risk estimation using early OGTT 75 g and/or glyFn results
Number of subjects: 748
Study 27733431 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-fluoride PET-CT with contrast-enhanced ECG-gated imaging
Number of subjects: 15
Study 27733431 — intervention group
Group type: COMPARATOR
Intervention: Nongated PET and noncontrast CT
Number of subjects: 15
Study 27733495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 0
Study 27733826 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Mirrors Intervention
Number of subjects: 0
Study 27733954 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (telephone-based, 12-week duration)
Number of subjects: 15
Study 27733954 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention
Number of subjects: 15
Study 27734949 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystinosis patients homozygous for the 57-kb deletion
Number of subjects: 0
Study 27734949 — intervention group
Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 0
Study 27736293 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 0
Study 27736293 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV (additional dose)
Number of subjects: 0
Study 27736293 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated against Streptococcus pneumoniae)
Number of subjects: 0
Study 27736729 — intervention group
Group type: EXPERIMENTAL
Intervention: KB004 (anti-EphA3 monoclonal antibody) administered by intravenous infusion on days 1, 8, and 15 of each 21-day cycle in escalating doses.
Number of subjects: 64
Study 27736729 — intervention group
Group type: EXPERIMENTAL
Intervention: KB004 (anti-EphA3 monoclonal antibody) administered by intravenous infusion.
Number of subjects: 64
Study 27737683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (body temperature below 36 °C)
Number of subjects: 525
Study 27737957 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hypertension
Number of subjects: 2604
Study 27737957 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated hypertension
Number of subjects: 2604
Study 27738789 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-cycle VMP schedule (4 cycles of twice weekly bortezomib) from VISTA trial
Number of subjects: 113
Study 27738789 — intervention group
Group type: COMPARATOR
Intervention: 6-cycle VMP schedule (1 cycle of twice weekly and 5 cycles of weekly bortezomib, then bortezomib-based maintenance) from PETHEMA/GEM05 trial
Number of subjects: 113
Study 27738920 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEIs/ARBs
Number of subjects: 926
Study 27738920 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 926
Study 27738920 — intervention group
Group type: EXPERIMENTAL
Intervention: BBs
Number of subjects: 926